Vaxine Pty Ltd is a rapidly growing Australian biotechnology company based in Adelaide that has developed an impressive pipeline of vaccines against infectious disease, allergy, and cancer. Vaxine has developed the Advax range of proprietary polysaccharide adjuvants and is currently applying this state of the art adjuvant technology to the development of vaccines against hepatitis B, pandemic influenza, Japanese encephalitis, West Nile virus, malaria, HIV and rabies, amongst others.

Vaxine developed CpG55.2, one of the first fully AI-designed drug molecules, to enter human trials (2019) and be in an approved human vaccine (2021) although admittedly not in the US.